Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI

Leuk Res. 2003 Aug;27(8):677-82. doi: 10.1016/s0145-2126(02)00343-0.

Abstract

Two novel stem cell factor (SCF) dependent human mast cell lines, designated LAD 1 and 2, were established from bone marrow aspirates from a patient with mast cell sarcoma/leukemia. LAD 1 and 2 cells have the ultrastructural features of human mast cells, and express FcepsilonRI, CD4, 9, 13, 14, 22, 31, 32, 45, 64, 71, 103, 117, 132, CXCR4 (CD184), CCR5 (CD195); and intracytoplasmic histamine, tryptase and chymase. LAD 1 and 2 do not exhibit activating mutations at codon 816 of c-kit. Both LAD 1 and 2 release beta-hexosaminidase following FcepsilonRI or FcgammaRI aggregation. The availability of these cell lines offers an unparalleled circumstance to examine the biology of human mast cells.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Bone Marrow Cells / pathology
  • Cell Division
  • Cell Line*
  • Dimerization
  • Humans
  • Immunophenotyping
  • Karyotyping
  • Leukemia, Mast-Cell / enzymology
  • Leukemia, Mast-Cell / genetics
  • Leukemia, Mast-Cell / pathology*
  • Male
  • Mast Cells / enzymology
  • Mast Cells / pathology*
  • Mast-Cell Sarcoma / enzymology
  • Mast-Cell Sarcoma / genetics
  • Mast-Cell Sarcoma / pathology*
  • Mutation
  • Receptors, IgE / metabolism
  • Receptors, IgG / metabolism
  • Stem Cell Factor / pharmacology

Substances

  • Receptors, IgE
  • Receptors, IgG
  • Stem Cell Factor